Aliases:This biomarker is also known as:
- breast and ovarian cancer sususceptibility protein 1,
- breast and ovarian cancer susceptibility protein 1,
- BRCA1/BRCA2-containing complex, subunit 1,
- EC 6.3.2.-,
- protein phosphatase 1, regulatory subunit 53,
- breast cancer type 1 susceptibility protein,
- RING finger protein 53,
- breast cancer 1, early onset,
BRCA1 is a nuclear phosphoprotein that functions as a tumor suppressor. BRCA1 combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). BRCA1 associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
BRCA1 is expressed in breast tissue and has been shown to be overexpressed in cancer.
BRCA1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.